Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

Gilead Sciences Inc

Start price
Target price
Perf. (%)
€78.68
28.10.22
-
28.10.23
-7.17%
18.05.23

Risky Investment
buy
Vertex Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€301.55
28.10.22
-
28.10.23
-10.79%
01.01.23

Risky Investment
buy
Vertex Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€301.55
28.10.22
-
28.10.23
-10.79%
01.01.23

Risky Investment
buy
Vertex Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€301.55
28.10.22
-
28.10.23
-10.79%
01.01.23

Risky Investment
buy
Davita Inc.

Start price
Target price
Perf. (%)
€73.02
28.10.22
-
0.45%
28.10.22

Risky Investment
buy
Twitter Inc.

Start price
Target price
Perf. (%)
€53.94
28.10.22
€160.00
28.10.23
-
29.10.22

Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Rising EBIT margin expected
buy
Orpea Nom.

Start price
Target price
Perf. (%)
€7.95
28.10.22
-
28.10.23
-16.20%
29.10.22

Could be very worthwhile Investment >20% year
buy
Apple Inc.

Start price
Target price
Perf. (%)
€147.06
28.10.22
-
28.10.23
-2.41%
03.11.22

Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
Very high dividend yield expected
EBIT growth > 30% per year expected
buy
Apple Inc.

Start price
Target price
Perf. (%)
€147.06
28.10.22
-
28.10.23
-2.41%
03.11.22

Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
Very high dividend yield expected
EBIT growth > 30% per year expected
buy
Apple Inc.

Start price
Target price
Perf. (%)
€147.06
28.10.22
-
28.10.23
-2.41%
03.11.22

Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
Very high dividend yield expected
EBIT growth > 30% per year expected
buy
Apple Inc.

Start price
Target price
Perf. (%)
€147.06
28.10.22
-
28.10.23
-2.41%
03.11.22

Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
Very high dividend yield expected
EBIT growth > 30% per year expected
buy
Baker Hughes A GE Co.

Start price
Target price
Perf. (%)
€27.00
27.10.22
€35.00
31.05.24
0.65%
21.12.22

Could be worthwhile Investment >10% per year
buy
Inventiva SA

Start price
Target price
Perf. (%)
€6.02
27.10.22
-
27.10.23
-42.03%
28.10.23

Could be worthwhile Investment >10% per year
Wolfspeed Inc.

Start price
Target price
Perf. (%)
€78.00
27.10.22
€32.00
27.10.23
-61.92%
27.10.23

buy
SAP SE

Start price
Target price
Perf. (%)
€98.19
27.10.22
€110.00
27.10.23
-0.81%
02.11.22

Could be worthwhile Investment >10% per year
buy
SAP SE

Start price
Target price
Perf. (%)
€98.19
27.10.22
€110.00
27.10.23
-0.81%
02.11.22

Could be worthwhile Investment >10% per year
buy
SAP SE

Start price
Target price
Perf. (%)
€98.19
27.10.22
€110.00
27.10.23
-0.81%
02.11.22

Could be worthwhile Investment >10% per year
buy
Deutsche Bank AG

Start price
Target price
Perf. (%)
€9.67
27.10.22
€15.00
27.10.23
0.98%
02.11.22

Could be worthwhile Investment >10% per year
buy
Deutsche Bank AG

Start price
Target price
Perf. (%)
€9.67
27.10.22
€15.00
27.10.23
0.98%
02.11.22

Could be worthwhile Investment >10% per year
buy
Linde plc

Start price
Target price
Perf. (%)
€293.35
27.10.22
€320.00
27.10.23
3.68%
02.11.22

Could be worthwhile Investment >10% per year
Meta Platforms Inc.

Start price
Target price
Perf. (%)
€105.26
27.10.22
€75.00
27.10.23
-5.09%
29.10.22

Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
Probably not worthwhile Investment
Meta Platforms Inc.

Start price
Target price
Perf. (%)
€105.26
27.10.22
€75.00
27.10.23
-5.09%
29.10.22

Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
Probably not worthwhile Investment
Meta Platforms Inc.

Start price
Target price
Perf. (%)
€105.26
27.10.22
€75.00
27.10.23
-5.09%
29.10.22

Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
Probably not worthwhile Investment
buy
Rocket Pharmaceuticals Inc

Start price
Target price
Perf. (%)
€17.96
26.10.22
€28.00
31.12.24
15.29%
08.06.24

Could be very worthwhile Investment >20% year
buy
Fate Therapeutics Inc.

Start price
Target price
Perf. (%)
€20.67
26.10.22
€35.00
31.12.24
-41.33%
21.12.22

Could be very worthwhile Investment >20% year